Información de la revista
Vol. 112. Núm. 9.
Páginas 864-865 (octubre 2021)
Vol. 112. Núm. 9.
Páginas 864-865 (octubre 2021)
Letter to the Editor
Open Access
Pityriasis Rosea in a Confirmed COVID-19 Pediatric Patient
Pitiriasis rosada en un paciente pediátrico con diagnóstico confirmado de COVID-19
I.N.S. Öncüa,
Autor para correspondencia

Corresponding author.
, D. Gülera, G. Gürela, G.Ş. Yalçınb
a Departamento de Dermatología, Facultad de Medicina, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey
b Departamento de Patología, Facultad de Medicina, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Descargar PDF
Figuras (2)
Texto completo
Dear Editor:

On December 31, 2019, the World Health Organization identified a novel coronavirus (SARS-CoV-2) in the city of Wuhan in China that spread very quickly and has to date resulted in the deaths of thousands of people by causing COVID-19 disease. Various Coronavirus disease-19 (COVID-19) associated dermatological manifestations have been reported. Among these, Pityriasis rosea (PR) and PR-like rash have been published previously. During the COVID-19 pandemic, the diagnosis of PR has become more common1–5.

PR is a self-limited inflammatory skin disease that can be induced viral agents especially HHV-6 (Human herpes virus 6), HHV-7 (Human herpes virus 7), autoimmunity, psychogenic factors, vaccines and drugs1,2.

We present here a case of PR in a confirmed COVID-19 pediatric patient.

A 10-year-old boy presented with a 20-day history of skin rash. It was learned that he had Covid-19 infection about 1 month ago and he did not use any medication. In dermatological examination, there were small plaques with erythema and collary scaly located parallel to the ribs on the body (Fig. 1). Complete blood count, liver and kidney function tests, hepatitis markers, sedimentation and CRP values were in normal ranges. Histopathology of one lesion's biopsy showed focal parakeratotic peaks, spongiosis, focal spongiotic vesiculation, lymphocyte exocytosis, mildly irregular acanthosis with mild homogenization of collagen in the dermis, mild to moderate perivascular erythocyte infiltration in the superficial vascular plexus, scattered lymphocyte infiltration, sparse lymphocytes was seen (Fig. 2). The diagnosis of PR after Covid -19 infection was established with clinical and histopathologic findings. The patient was treated with betamethasone valerate ointment, 10% urea and cetirizine. Lesions regressed one month later.

Figure 1.

Diffuse erythematous lesions on the trunk and many of lesions had peripheral scales.

Figure 2.

Focal mounds of parakeratosis, mild exocytosis of lymphocytes, mild perivascular mononuclear inflammatory cells and some extravasated erythocytes (Hematoxylin & eosin, ×200).


The association between PR and COVID‐19 infection is not clearly known. In the literature, patients with confirmed COVID-19 developed PR and PR-like rash, some of them while asymptomatic or symptomatic disease, others after COVID-19 infection2–5. Therefore, in a patient presenting with PR and PR-like rash, it is necessary to keep in mind Covid-19 infection and suggest SARs-CoV-2 testing for necessary patients. PR could be directly dependent to COVID-19 infection, or to viral reactivation (HHV-6, HHV-7, EBV)1–5. In addition, the increased psychological stress caused by the pandemic period may have contributed to the trigger1. Due to the limited number of data, it is very difficult to prove a causal relation in these cases.

In conclusion, dermatologists should be aware that cutaneous symptoms may be linked to COVID-19 infection.


The patient and his family in this manuscript have given written informed consent to publication of his case details.

R. Dursun, S.A. Temiz.
The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease.
Dermatol Ther., 33 (2020),
S. Veraldi, M. Romagnuolo, V. Benzecry.
Pityriasis rosea-like eruption revealing COVID-19.
Australas J Dermatol., 10 (2020), pp. 1111
F. Drago, G. Ciccarese, A. Rebora, A. Parodi.
Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19.
J Med Virol., 24 (2020), pp. 1002
S. Veraldi, C.B. Spigariolo.
Pityriasis rosea and COVID-19.
J Med Virol., 18 (2020), pp. 1002
M. Johansen, S.S. Chisolm, L.D. Aspey, M. Brahmbhatt.
Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: a report of 2 cases.
JAAD Case Rep., 7 (2021), pp. 93-94

Please cite this article as: Öncü INS, Güler D, Gürel G, Yalçın GŞ. Pitiriasis rosada en un paciente pediátrico con diagnóstico confirmado de COVID-19. Actas Dermosifiliogr. 2021;112:864–865.

Actas Dermo-Sifiliográficas
Opciones de artículo
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?